Receptor‐mediated autocrine growth‐stimulatory effect of 5‐hydroxytryptamine on cultured human pancreatic carcinoid cells
- 1 January 1992
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 150 (1) , 1-7
- https://doi.org/10.1002/jcp.1041500102
Abstract
5-hydroxytryptamine (5-HT) is a mitogen for fibroblasts, vascular smooth muscle cells, renal mesangial cells, and jejunal crypt cells. The human carcinoid cell line (termed BON) that we established in our laboratory from a pancreatic carcinoid tumor produces and secretes 5-HT. In this study, therefore, we examined the effect of 5-HT on growth of BON cells. Furthermore, by use of selective 5-HT receptor antagonists, we examined receptor and post-receptor mechanisms by which 5-HT-induced responses were produced. 5-HT stimulated growth of BON cells. 5-HT stimulated phosphatidylinositol (PI) hydrolysis in a dose-dependent fashion and inhibited cyclic AMP production in a dose-dependent fashion. The 5-HT1A/1B receptor antagonist, SDZ 21–009, prevented the reduction of cyclic AMP production evoked by 5-HT and inhibited the mitogenic action of 5-HT. The 5-HT1C/2 receptor antagonist, mesulergine, competitively inhibited PI hydrolysis, but did not affect the mitogenic action of 5-HT. The mitogenic action of 5-HT and the reduction of cyclic AMP production evoked by 5-HT were also inhibited by pertussis toxin. These results suggest that 5-HT is an autocrine growth factor for BON cells and that mitogenic mechanism of 5-HT involves receptor-mediated toxin-sensitive GTP binding protein. 8-bromo-cyclic AMP inhibited growth of BON cells whereas 8-bromo-cyclic GMP had no effect on cell growth. Involvement of protein kinase A in BON cell growth regulation was confirmed by the observation that a cAMP-dependent protein kinase antagonist (Rp-cAMPS) could stimulate BON cell growth.Keywords
This publication has 24 references indexed in Scilit:
- Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brainTrends in Pharmacological Sciences, 1989
- Therapeutic Considerations for the Malignant Carcinoid SyndromeActa Oncologica, 1989
- Serotonin stimulates DNA synthesis in fibroblasts acting through 5–HT1B receptors coupled to a Gi-proteinNature, 1988
- Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist.BMJ, 1987
- Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (−)[125I]iodocyanopindolol, [3H]mesulergine and [3H]KetanserinEuropean Journal of Pharmacology, 1985
- The Pentagastrin Test in the Diagnosis of the Carcinoid SyndromeAnnals of Surgery, 1985
- Islet-activating protein, pertussis toxin: a probe for functions of the inhibitory guanine nucleotide regulatory component of adenylate cyclaseTrends in Pharmacological Sciences, 1984
- EVIDENCE FOR THE SYNTHESIS AND STORAGE OF 5‐HYDROXYTRYPTAMINE IN TWO SEPARATE POOLS IN THE BRAINJournal of Neurochemistry, 1973
- Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, broncho-constriction, and an unusual type of cyanosisAmerican Heart Journal, 1954
- 5-Hydroxytryptamine in a Carcinoid TumourNature, 1953